These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 16543059)

  • 1. Towards immunogene therapy of hematological malignancies.
    Ivanov R; Hagenbeek A; Ebeling S
    Exp Hematol; 2006 Mar; 34(3):251-63. PubMed ID: 16543059
    [No Abstract]   [Full Text] [Related]  

  • 2. Allogeneic cell-mediated immunotherapy at the stage of minimal residual disease following high-dose chemotherapy supported by autologous stem cell transplantation.
    Slavin S
    Acta Haematol; 2005; 114(4):214-20. PubMed ID: 16269861
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Donor lymphocyte infusion. An adaptive cellular immunotherapy for treatment of hematological malignancies.
    Owaidah TM
    Saudi Med J; 2003 Feb; 24(2):138-41. PubMed ID: 12682675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hematopoietic stem cell transplant as a platform for tumor immunotherapy.
    Fuchs EJ; Whartenby KA
    Curr Opin Mol Ther; 2004 Feb; 6(1):48-53. PubMed ID: 15011781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cellular immunotherapy of hematologic malignancies attempted using minor histocompatibility antigens as targets].
    Takami A; Shiobara S
    Rinsho Ketsueki; 2002 May; 43(5):360-2. PubMed ID: 12096487
    [No Abstract]   [Full Text] [Related]  

  • 6. T-cell therapy after hematopoietic stem cell transplantation.
    Kennedy-Nasser AA; Brenner MK
    Curr Opin Hematol; 2007 Nov; 14(6):616-24. PubMed ID: 17898565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Defining the Role of Donor Lymphocyte Infusion in High-Risk Hematologic Malignancies.
    Schmid C; Kuball J; Bug G
    J Clin Oncol; 2021 Feb; 39(5):397-418. PubMed ID: 33434060
    [No Abstract]   [Full Text] [Related]  

  • 8. Gene therapy for hematological malignancies.
    Schmidt-Wolf GD; Schmidt-Wolf IG
    Clin Exp Med; 2003 May; 3(1):4-14. PubMed ID: 12748873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Modern therapy of hematologic malignancies].
    Trnĕný M
    Cas Lek Cesk; 2001 Nov; 140(23):711-6. PubMed ID: 11787232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Graft-versus-host and graft-versus-leukemia reactions: a summary of the Seventh International Symposium held in Garmisch-Partenkirchen, Germany, February 22nd-25th, 2006, Tolerance and Immunity, an update on lymphoid malignancies.
    Munker R; Reibke R; Kolb HJ
    Bone Marrow Transplant; 2006 Nov; 38(9):593-607. PubMed ID: 16980992
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New immunotherapy-based approach in allogeneic hematopoietic stem cell transplantation.
    Maeda Y
    Int J Hematol; 2018 Feb; 107(2):129. PubMed ID: 29260506
    [No Abstract]   [Full Text] [Related]  

  • 13. Immunotherapy by allogeneic stem cell transplantation.
    Ringdén O
    Adv Cancer Res; 2007; 97():25-60. PubMed ID: 17419940
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune reconstitution following myeloablative allogeneic hematopoietic stem cell transplantation: the impact of expanding CD28negative CD8+ T cells on relapse.
    Yakoub-Agha I; Saule P; Magro L; Cracco P; Duhamel A; Coiteux V; Bruno B; Dufossé F; Jouet JP; Dessaint JP; Labalette M
    Biol Blood Marrow Transplant; 2009 Apr; 15(4):496-504. PubMed ID: 19285638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for treatment of hematological malignancies in children.
    Liu D; Huang X; Liu K; Xu L; Chen H; Han W; Chen Y; Zhang X; Jiang Q
    Biol Blood Marrow Transplant; 2008 Apr; 14(4):469-77. PubMed ID: 18342790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk factors associated with late cytomegalovirus reactivation after allogeneic stem cell transplantation for hematological malignancies.
    Ozdemir E; Saliba RM; Champlin RE; Couriel DR; Giralt SA; de Lima M; Khouri IF; Hosing C; Kornblau SM; Anderlini P; Shpall EJ; Qazilbash MH; Molldrem JJ; Chemaly RF; Komanduri KV
    Bone Marrow Transplant; 2007 Jul; 40(2):125-36. PubMed ID: 17530009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Graft-versus-disease effect following allogeneic transplantation for acute leukaemia.
    Rowe JM
    Best Pract Res Clin Haematol; 2008 Sep; 21(3):485-502. PubMed ID: 18790451
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relevance of KIR gene matching in unrelated hematopoietic stem cell transplantations.
    Gagne K; Busson M; Balere-Appert ML; Absi L; Jollet I; Bignon JD; Bois M; Dormoy A; Dubois V; Gebuhrer L; Loiseau P; Masson D; Moine A; Perrier P; Reviron D; Charron D; Raffoux C;
    Tissue Antigens; 2007 Apr; 69 Suppl 1():118-22. PubMed ID: 17445183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-CD34+ cells, especially CD8+ cytotoxic T cells and CD56+ natural killer cells, rather than CD34 cells, predict early engraftment and better transplantation outcomes in patients with hematologic malignancies after allogeneic peripheral stem cell transplantation.
    Kim DH; Won DI; Lee NY; Sohn SK; Suh JS; Lee KB
    Biol Blood Marrow Transplant; 2006 Jul; 12(7):719-28. PubMed ID: 16785061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapy of hematological malignancies with dendritic cells.
    Falkenburg JH
    Hematol J; 2004; 5 Suppl 3():S96-9. PubMed ID: 15190287
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.